RNAi Oligonucleotides Targeting TSC2 for Retinal Dystrophies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinal dystrophies, such as retinitis pigmentosa and Leber's congenital amaurosis, are limited in effectiveness and specificity, particularly in addressing the underlying genetic mutations and photoreceptor degeneration.
Innovation Solution
The use of RNAi oligonucleotides and siRNA molecules specifically targeted to the TSC2 gene, with optional targeting of the TSC1 gene, to modulate and reduce their expression in ocular cells, thereby managing retinal dystrophies and photoreceptor death.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current treatments for retinal dystrophies are used, then general symptom management is achieved, but specificity in addressing underlying genetic mutations and photoreceptor degeneration is limited
Solution Approach 1:
The patent segments the treatment approach by developing separate siRNA molecules that specifically target different genetic pathways involved in retinal dystrophies. Each siRNA is designed to bind to specific mRNA sequences, enabling precise targeting of disease-causing genes while leaving other cellular functions intact. This segmentation allows for customized treatment strategies based on the specific genetic mutation present in each patient.
Solution Approach 2:
The patent introduces siRNA molecules as intermediary agents that mediate between the administered treatment and the target genetic material. These siRNAs act as intermediaries by first binding to complementary mRNA sequences, then recruiting RNA-induced silencing complex (RISC) to degrade the target mRNA, thereby indirectly preventing the production of harmful proteins without directly interacting with the genetic DNA.
2Reliability
If RNAi oligonucleotides targeting TSC2 and TSC1 genes are used, then photoreceptor survival is improved, but treatment complexity increases
Solution Approach 1:
The patent employs preliminary action by designing and pre-synthesizing stable siRNA oligonucleotides with optimized sequences before administration. The siRNAs are pre-modified with chemical groups to enhance their stability and resistance to degradation by nucleases in the ocular environment. This preliminary preparation ensures that the treatment molecules remain intact long enough to reach their target genes and exert their protective effect on photoreceptors.
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure of the siRNA oligonucleotides to optimize their pharmacokinetic properties. Chemical modifications such as 2'-O-methyl substitutions and phosphorothioate backbone modifications are introduced to change parameters like serum stability, cellular uptake efficiency, and off-target binding affinity, thereby improving therapeutic outcomes while managing treatment complexity.
3Duration of action of moving object
If siRNA molecules are used to block protein synthesis, then long-lasting therapeutic effect is achieved, but potential off-target effects may increase
Solution Approach 1:
The patent applies local quality by designing siRNA molecules with region-specific binding properties. Each siRNA is engineered to bind to a unique, localized sequence within the target mRNA that is distinct from other cellular RNAs. This localized specificity ensures that the gene silencing effect is confined to the intended target gene and does not inadvertently affect other genes or cellular processes, thereby reducing off-target effects while maintaining long-lasting therapeutic action.
Solution Approach 2:
The patent incorporates feedback mechanisms by designing control strategies that monitor treatment response and adjust dosing accordingly. Clinical monitoring of photoreceptor function and gene expression levels provides feedback information that allows clinicians to optimize the frequency and dosage of siRNA administrations, maximizing therapeutic benefit while minimizing the risk of off-target effects through personalized treatment adjustment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a specific and long-lasting therapeutic effect by blocking the synthesis of TSC2 and TSC1 proteins, potentially reducing side effects and improving photoreceptor survival and visual function in patients with retinal dystrophies.
Implementation Method 1
RNAi is a naturally occurring post-transcriptional regulatory mechanism present in most eukaryotic cells that uses small double stranded RNA (dsRNA) molecules to direct homology-dependent gene silencing
Implementation Method 2
such as small interfering RNA (siRNA) compounds or molecules, which in embodiments hybridize with nucleic acid molecules encoding either or both of TSC1 and/or TSC2
Data Source
Figure 1
Figure 1
Figure 2
AI summary
RNA interfering oligonucleotides targeting TSC2 are described for the treatment of retinal dystrophies. The RNAi oligonucleotides may be siRNAs, and may further comprise siRNAs targeting TSC1. Branched oligonucleotides comprising two or more siRNAs and product combinations of two or more different siRNAs are described, which in embodiments may target either or both of TSC1 and/or TSC2. The invention also relates to methods and compositions comprising such products.